Investigation Reveals Financial Shifts in 340B Drug Pricing Program, Raising Concerns Over Patient Care

A recent audit conducted by ADAP Advocacy in collaboration with the Community Access National Network (CANN) has uncovered significant financial changes within the 340B Drug Pricing Program. The investigation, which examined 33 healthcare institutions, revealed an average revenue increase of 772.92% and a 237.11% rise in executive compensation, alongside a 34.80% decrease in charity care as a percentage of annual revenues.

Brandon M. Macsata, CEO of ADAP Advocacy, pointed out the growing gap between the program's original mission to aid vulnerable populations and its current focus, which seems to favor provider benefits over patient needs. The findings, detailed in the report titled 'The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities–Supplemental Report,' are available for download on the ADAP Advocacy website.

This report sheds light on the evolving dynamics of the 340B program, prompting a reevaluation of its structure to ensure it meets its foundational objectives of supporting underserved patients.